Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling
Israeli Firm Is On Hook Again For $235m Payment
Teva has once again been instructed to compensate GSK with $235m in damages after a split US Court of Appeals reversed a lower court finding that Teva had not willfully induced infringement of a method-of-use patent shielding the originator’s Coreg antihypertensive.
